Merck, Eli Lilly, and Biogen committed over $12 billion in recent acquisitions, including Merck's $5.7B-$6.7B deal for Terns Pharmaceuticals, Eli Lilly's $6.3B acquisition of Centessa Pharmaceuticals, and Biogen's purchase of Apellis Pharmaceuticals. 1 2 This M&A wave is described as a dominant trend in oncology biotech, accelerating capital deployment amid patent cliffs and AI-biology partnerships like Insilico Medicine’s $2.75B Lilly deal. 1 Post-Hoc Live discussions highlight improving biotech sentiment, with expectations of continued M&A activity due to low valuations and market recovery, as noted in Endpoints News and HBM Healthcare outlooks. 3 4 Additional deals include Novartis’ up to $2B for Excellergy and Gilead’s $2.1B for Ouro Medicines, pushing total biopharma spending beyond $20B. 2 The sector shows strategic capital use for pipeline bolstering, regulatory wins, and clinical advancements. 1 2 Sources: 1. https://oncodaily.com/techology/ai479...
- Get link
- X
- Other Apps